Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Expression of the major intracellular serine protease (
ISP
-1) gene of Bacillus subtilis was studied by using a translational fusion plasmid in which the isp promoter region was fused to the lacZ gene. beta-Galactosidase activity, used to measure transcription from the isp promoter, was produced immediately after the end of exponential growth, whereas intracellular protease activity was not detected until 4 h later. These results are consistent with a previous suggestion that
ISP
-1 initially accumulates in the cell in an enzymatically inactive form.
ISP
-1 activity was detected in all of the sporulation-deficient strains examined, and the amount of protease activity always corresponded to the amount of
beta-galactosidase
activity. These results indicate that the activation of
ISP
-1 is not dependent on a sporulation-specific gene product. Expression of
ISP
-1 is regulated by a number of mutations known to affect the expression of extracellular enzymes. In sacU(h) and sacQ(h) mutants, the expression of
ISP
-1 was 10-fold higher than in the wild-type strain. In catA, hpr, and scoC strains, expression of
ISP
was stimulated two- to threefold, whereas in sacU mutants the expression of
ISP
-1 was reduced to less than 10% of the wild-type level. The temporal expression and activation of
ISP
-1 was not affected by any of these mutations. This is the first evidence that the expression of a native intracellular protein is affected by these hyperproduction mutations.
...
PMID:Control of intracellular serine protease expression in Bacillus subtilis. 312 83
